Effect of 18F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer

Groheux, David; Moretti, Jean‐Luc; Baillet, G.; Espié, Marc; Giacchetti, Sylvie; Hindié, Elif; Hennequin, Christophe; Vilcoq, Jacques R.; Cuvier, C.; Toubert, Marie‐Elisabeth; Filmont, Jean-Emmanuel; Sarandi, Farid; Misset, Jean-Louis

doi:10.1016/j.ijrobp.2008.02.056

Cited by 110 publications

(84 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the limited spatial resolution, FDG PET can miss small lesions, and this is especially true for low-grade tumours and lobular carcinoma [10]. In a recent study, among 32 invasive tumours >2 cm, 31 (97%) were well visualized with FDG PET [8]. PET might, however, miss additional small foci of breast cancer.…”

Section: Primary Tumour Assessmentmentioning

confidence: 99%

“…Depicting lymph node involvement in levels or basins other than those addressed by routine ALND may have major impact on treatment strategies. Many studies suggest that FDG PET performs better than conventional imaging in depicting involvement in high-level axillary (Berg level III) as well as in supraclavicular and internal mammary lymph nodes [8,9,[13][14][15]. PET/CT is particularly appealing compared to PET alone as it provides the precise location of involved nodes [7][8][9].…”

Section: Axillary and Extra-axillary Lymph Node Stagingmentioning

confidence: 99%

“…Differentiating level III axillary lymph nodes (infraclavicular lymph nodes located superomedially to the pectoralis minor muscle) is important since axillary clearance usually addresses Berg level I and II nodes only. Surgical studies have demonstrated that level III node involvement (N3a) results in a poorer prognosis [16]; a modified surgical approach is then useful [8].…”

Section: Axillary and Extra-axillary Lymph Node Stagingmentioning

confidence: 99%

“…Patients with supraclavicular lymph nodes (N3c) can receive more intensive treatment combining induction chemotherapy, surgery, postsurgical chemotherapy and irradiation, which improves the disease-free survival and overall survival [17]. Again, visualization of an internal mammary hot node on initial PET/CT can lead to the decision on surgery and/or radiotherapy [8].…”

Section: Axillary and Extra-axillary Lymph Node Stagingmentioning

confidence: 99%

“…Several studies have documented the value of 18 F-FDG PET in locally advanced and inflammatory breast cancer [6,7], but also in populations comprising clinical stage II patients [8,9].…”

mentioning

confidence: 99%

See 4 more Smart Citations

Should FDG PET/CT be used for the initial staging of breast cancer?

Groheux

Hindié

Rubello

et al. 2009

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Section: Primary Tumour Assessmentmentioning

confidence: 99%

Section: Axillary and Extra-axillary Lymph Node Stagingmentioning

confidence: 99%

Section: Axillary and Extra-axillary Lymph Node Stagingmentioning

confidence: 99%

Section: Axillary and Extra-axillary Lymph Node Stagingmentioning

confidence: 99%

“…Several studies have documented the value of 18 F-FDG PET in locally advanced and inflammatory breast cancer [6,7], but also in populations comprising clinical stage II patients [8,9].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Should FDG PET/CT be used for the initial staging of breast cancer?

Groheux

Hindié

Rubello

et al. 2009

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

18F‐fluorodeoxyglucose positron emission tomography/computed tomography (FDG‐PET/CT) imaging in the staging and prognosis of inflammatory breast cancer

Alberini

Lerebours

Fourme

et al. 2009

Cancer

111

View full text Add to dashboard Cite

show abstract

Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer

Morris

Ulaner

Eaton

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND:In this retrospective, single-institution study, the authors examine the maximum standardized uptake value (SUVmax) on positron emission tomography/computed tomography (PET/CT) images as a prognostic variable in patients with newly diagnosed metastatic breast cancer (MBC). METHODS: Patients with !1 metastatic lesion on PET/CT images that were obtained within 60 days of their MBC diagnosis between January 1, 2001 and December 31, 2008 were included. Patients were excluded if they had received chemotherapy 30 days before the PET/CT images were obtained. Electronic medical reports were reviewed to determine the SUVmax and overall survival. Because of intraindividual variation in the SUV by body site, separate analyses were conducted by metastatic site. Relationships between site-specific PET/CT variable tertiles and overall survival were assessed using Cox regression; hazard ratios for the highest tertile versus the lowest tertile were reported. RESULTS: In total, 253 patients were identified, and their median age was 57 years (range, 27-90 years). Of these, 152 patients (60%) died, and the median follow-up was 40 months. On univariate analysis, SUVmax tertile was strongly associated with overall survival in patients who had bone metastases (N ¼ 141; hazard ratio, 3.13; 95% confidence interval, 1.79-5.48; P < .001). This effect was maintained on multivariate analysis (HR ¼ 3.19; 95% confidence interval, 1.64-6.20, P ¼ .002) after correcting for known prognostic variables. A greater risk of death was associated with SUVmax tertile in patients who had metastases to the liver (N ¼ 46; hazard ratio, 2.07; 95% confidence interval, 0.90-4.76), lymph nodes (N ¼ 149; hazard ratio, 1.1; 95% confidence interval, 0.69-1.88), and lung (N ¼ 62; hazard ratio, 2.2; 95% confidence interval, 0.97-4.95), although these results were not significant (P ¼ .18, P ¼ .31, and P ¼ .095, respectively). CONCLUSIONS: The current results indicate that PET/CT has value as a prognostic tool in patients with newly diagnosed MBC to bone. Cancer 2012;118:5454-62. V C 2012 American Cancer Society.KEYWORDS: metastatic breast cancer, positron emission tomography/computed tomography, maximum standardized uptake value, prognosis, overall survival. INTRODUCTIONMetastatic breast cancer (MBC) represents a significant public health problem, because approximately 33% of the 1 million women who are diagnosed annually worldwide with early stage disease eventually will experience relapse, and a smaller number of patients present de novo with this disease. 1 After diagnosing MBC, clinicians and patients can use prognostic information to guide the selection of appropriate therapies to improve quality of life and maximize survival. Currently available prognostic tools focus on several clinicopathologic features, such as age and time from diagnosis of primary breast cancer, as well as tumor-related factors, like expression levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Although useful, t...

show abstract

Effect of 18F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer

Cited by 110 publications

References 32 publications

Should FDG PET/CT be used for the initial staging of breast cancer?

Should FDG PET/CT be used for the initial staging of breast cancer?

18F‐fluorodeoxyglucose positron emission tomography/computed tomography (FDG‐PET/CT) imaging in the staging and prognosis of inflammatory breast cancer

Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer

Contact Info

Product

Resources

About